Tech Company Financing Transactions
Aeonian Pharmaceuticals Funding Round
Aeonian Pharmaceuticals closed a Seed investment round on 12/13/2017. Investors included Apollo Ventures and private investors.
Transaction Overview
Company Name
Announced On
12/13/2017
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Apollo Ventures (Lead Investor) (James Peyer)
Proceeds Purpose
Aeonian expects to use the proceeds from the transaction to advance its pipeline of innovative therapeutic candidate programs based on its discovery of the most highly selective inhibitors of the mTORC1 pathway ever discovered.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Aeonian Pharmaceuticals, Inc. is an R&D-stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stelios Tzannis
Chief Operating Officer
Benjamin Zadik
Chief Scientific Officer
David Lowe
VP - Bus. Development
Ian Massey
Browse more venture capital transactions:
Prev: 12/12/2017: Menlo Security venture capital transaction
Next: 12/13/2017: ShieldX venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document all VC transactions involving tech companies. VC investment data records reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs